Aktuellt
SENASTE
The Committee for Medicinal Products for Human Use (CHMP) of EMA recommends a full marketing authorisation for Kinpeygo in Europe and a target patient population of UPCR of ≥ 0.8g/g. EC can expect to make the formal decision by August 2024. Yesterday, Calliditas also provided an R&D update, including the lead product, Nefecon.
LÄS MER
